Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer

Journal of Urology

Volumn 182, Issue 1, 2009, Pages 317-323

  Vaishampayan, Ulka N ^a   Marur, Shanthi ^a   Heilbrun, Lance K ^b   Cher, Michael L ^a   Dickow, Brenda ^a   Smith, Daryn W ^b   Al Hasan, Samir A ^c   Eliason, James ^a,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Asterand   (United States)

Author keywords

capecitabine; docetaxel; neoplasm metastasis; prostate; prostatic neoplasms

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; SYNTHETASE; THYMIDINE PHOSPHORYLASE; THYMIDINE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG POTENTIATION; EDEMA; FATIGUE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LACRIMATION DISORDER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 67349278293     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.02.105     Document Type: Article

References (19)

1. Tannock I., DeWit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
2. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
3. Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., Ishitsuka H., et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 (1998) 1013
4. Schilsky R.L. Pharmacology and clinical status of capecitabine. Oncology (Huntingt) 14 (2000) 1297
5. Touffet S., Gayet G., Samperez S., and Jouan P. Demonstration of thymidine phosphorylase activity in human healthy adenomatous and cancerous prostate. Bull Cancer 79 (1992) 151
6. Okada K., Yokoyama K., Okihara K., Ukimura O., Kojima M., Miki T., et al. Immunohistochemical localization of platelet derived endothelial cell growth factor expression and its relation to angiogenesis in prostate. Urology 57 (2000) 376
7. Takebayashi Y., Yamada K., Miyadera K., Sumizawa T., Furakawa T., Kinoshita F., et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 32A (1996) 1227
8. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., and Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine, and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 (1998) 685
9. Qiu L.X., Tang Q.Y., Bai J.L., Qian X.P., Li R.T., Liu B.R., et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine based chemotherapy: evidence from 24 studies. Int J Cancer 123 (2008) 2384
10. Nadella P., Shapiro C., Otterson G., Hauger M., Erdal S., and Kraut E. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20 (2002) 2616
11. Pronk L.C., Vasey P., Sparreboom A., Reigner B., Planting A.S., Gordon R.J., et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer 83 (2000) 22
12. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812
13. Therasse P., Arbuck S.G., Eisenhauer Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205
14. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461
15. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10 (1989) 1
16. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., and Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396
17. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232
18. Ferrero J.M., Chamorey E., Oudard S., Dides S., Lesbats G., Cavaglione G., et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 107 (2006) 738
19. Kolodziej M., Neubauer M.A., Rousey R., Pluenneke R.E., Perrine G., Mull S., et al. Phase II trial of docetaxel/capecitabine in hormone refractory prostate cancer. Clin Genitourin Cancer 5 (2006) 155